Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07207369

A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

Atrophic acne scars are flat, indented or with an inverted center scars that develop at the endpoint of the normal healing process for acne. Acne scarring that remains after acne resolves has a significant impact on health related quality of life, including reduced self-esteem and embarrassment/self consciousness. ELAPR002f provides an immediate space-occupying effect for filling in the scar tissue. The purpose of this study is to assess how safe and effective ELAPR002f injectable gel is on adult participants with atrophic acne scars.

ELAPR002f injectable gel is an investigational device being developed for the treatment of facial atrophic acne scars. There are 2 cohorts in this study. In Cohort 1, all participants will receive ELAPR002f injectable gel. In Cohort 2, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to the saline active control group. Around 395 adult participants with moderate to severe atrophic acne scarring on both cheeks will be screened in the study in approximately 25 sites in the United States.

Participants will receive 3 treatments over 2 months of intradermal injections of either ELAPR002f injectable gel or saline active control and will be followed for up to an additional 12 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acne Scars

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Advanced Research Associates - Glendale /ID# 254961, Glendale, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants in general good health, and seeking improvement of atrophic acne scars.
  • Moderate to severe atrophic acne scarring (Grade 4 or 5 on the Allergan Acne Scar Improvement Scale [ASIS]) on each cheek based on evaluating investigator (EI) live assessment (both cheeks must qualify but do not need to have the same score) at the first Screening Visit.
  • At least 5 rolling or boxcar-type acne scars in total within the predefined 4 cm × 4 cm assessment field of either cheek in areas of otherwise normal healthy skin, as assessed by the treating investigator (TI).

Exclusion criteria

  • The participant has clinically significant acne on the face.
  • Current cutaneous or mucosal inflammatory or infectious processes other than acne (eg, herpes), rosacea, abscess, an unhealed wound, or a cancerous or precancerous lesion, on the face.
  • The participant presents with predominantly ice pick scars.
  • History of keloid scar formation, hypertrophic scarring, and/or post inflammatory hyperpigmentation or hypopigmentation.

Treatment and study plan

ELAPR002f Injectable Gel

Device

Intradermal Injections

Saline Control

Device

Intradermal Injections

Primary outcomes

  1. Percentage of Participants who Achieve a 20% Reduction in Acne Scar Area

    Time frame: Baseline to Day 181

    The acne scar area is calculated from 3D camera imaging software. Area is defined as the sum of the individual scar area of the 5 most prominent scars identified by the treating investigator (TI).

  2. Number of Participants with Adverse Events

    Time frame: Up to Day 420

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

  3. Number of Participants with Presence of Binding Antibodies

    Time frame: Up to Day 420

    Presence of binding antibodies followed by characterization through isotyping and evaluation of cross-reactivity to endogenous tissues.

  4. Number of Participants with Injection Site Responses (ISRs) and Systemic Responses

    Time frame: Up to Day 420

    Incidence of ISRs/systemic responses as recorded by e-diary. ISRs are defined as redness, pain after injection, tenderness to touch, firmness, swelling, lumps/bumps, bruising, itching and discoloration (not redness or bruising).

  5. Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters

    Time frame: Up to Day 420

    Vital sign parameters include body temperature, systolic and diastolic blood pressure, pulse rate, and respiratory rate. The investigator will assess the results for clinical significance.

  6. Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters

    Time frame: Up to Day 420

    Clinical laboratory parameters include tests of hematology, chemistry, and urinalysis. The investigator will assess the results for clinical significance.

  7. Number of Participants With Clinically Significant Changes From Baseline in Physical Measurements

    Time frame: Up to Day 420

    Physical measurements include weight and BMI. The investigator will assess the results for clinical significance.

  8. Change from Baseline Procedure Pain

    Time frame: Up to Day 420

    Participants will assess procedure pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable) after each of the 3 treatment sessions.

  9. Number of Participants with a Positive Skin Test

    Time frame: Up to Day 420

    Participants will undergo a skin test in the volar area of the forearm to test for hypersensitivity.

  10. Number of Participants with Visual Disturbance Symptoms Associated with Vascular Occlusion

    Time frame: Up to Day 420

    Number of participants with any acute cognitive changes or any change in confrontational visual fields, ocular motility, or a worsening (1-line change or more) on the Snellen visual acuity assessment.

  11. Number of Participants Needing a Histology of Volar Forearm Site Biopsy

    Time frame: Up to Day 420

    Participants who are suspected of having a hypersensitivity reaction or have a hypersensitivity reaction to the volar forearm injection site will require a punch biopsy of the volar forearm injection site.

Secondary outcomes

  1. Change from Baseline on the Overall Score of ACNE-Q Acne Scars Questionnaire

    Time frame: Up to Day 420

    The ACNE-Q Acne Scars questionnaire includes 10 questions that ask how much the participant is bothered by their acne scars on a 4-point scale ranging from 1=Not at all to 4=Very Much.

  2. Change from Baseline on the Overall Score of ACNE-Q - Appearance-Related Distress

    Time frame: Up to Day 420

    ACNE-Q - Appearance-Related Distress questionnaire includes 8 questions that ask about how the participants describe themselves on a 4-point scale ranging from 1=Never to 4=Always.

  3. Change from Baseline on the Overall Score of FACE-Q Satisfaction with Skin Total Score

    Time frame: Up to Day 420

    FACE-Q Satisfaction With Skin questionnaire includes 12 questions that ask how much the participants are satisfied or dissatisfied with their facial skin on a 4-point scale ranging from 1=Very Dissatisfied to 4=Very Satisfied.

  4. Percentage of Participants Achieving "Responder" Status on Either Cheek Based on the Allergan Acne Scar Improvement Scale (ASIS), as assessed by the Evaluating Investigator

    Time frame: Up to Day 420

    A "responder" is a participant who achieves 1-grade improvement on either cheek based on the ASIS, as assessed by the EI. The ASIS is a 5-grade scale used to assess acne scar improvement ranging from 1=Almost None to 5=Severe. Each side of the face is scored separately.

  5. Percentage of Participants who Achieve a 20% Reduction in Acne Scar Area

    Time frame: Up to Day 420

    The acne scar area is calculated from 3D camera imaging software. Area is defined as the sum of the individual scar area of the 5 most prominent scars identified by the treating investigator (TI).

  6. Percent Change from Baseline in Acne Scar Area

    Time frame: Up to Day 420

    The acne scar area is measured by 3D camera imaging software. Area is defined as the sum of the individual scar area of the 5 most prominent scars identified by the TI.

  7. Percent Change from Baseline in Acne Scar Volume

    Time frame: Up to Day 420

    The acne scar volume is measured by 3D camera imaging software. Volume is defined as the sum of the individual scar volume of the 5 most prominent scars identified by the TI.

Study contacts

Contact information is provided by the study sponsor or research team.

ABBVIE CALL CENTER

CONTACT

[email protected]

844-663-3742

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Official study title

A Multicenter, Cohort-design, Double-blind, Randomized, Parallel-group, Controlled Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Oct 6, 2025
Registry last updated
Nov 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.